Smith Jason Drew

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$78,550.00
Insider Sells Quantity
9
Insider Sells Sum
$419,357.89

Insider Activity of Smith Jason Drew

According to the SEC Form 4 filings, Smith Jason Drew, being in a position of

  1. General Counsel at UroGen Pharma Ltd.,
    оver the last 12 months, has bought 0 shares, and sold 8900 shares for $102,097,
    over all time since 2021-05-17, has bought 5000 shares for $78,550, and sold 32145 shares for $419,358.

The largest purchase of all time was on 2021-05-17 and amounted to 5000 shares of UroGen Pharma Ltd. for $78,550.

The largest sale of all time was on 2025-01-31 and amounted to 7379 shares of UroGen Pharma Ltd. for $82,202.

Biography of Smith Jason Drew

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$102,0972100

Comparison of Insiders on Amount of Buys and Sells

2025-01-31SaleUroGen Pharma Ltd.
URGN
General Counsel
7,379
0.0172%
$11.14$82,202-2.82%
2024-09-09SaleUroGen Pharma Ltd.
URGN
General Counsel
1,521
0.0035%
$13.08$19,895-14.23%
2024-02-01SaleUroGen Pharma Ltd.
URGN
General Counsel
4,993
0.0162%
$15.78$78,790-14.81%
2024-01-31SaleUroGen Pharma Ltd.
URGN
General Counsel
4,993
0.0161%
$15.74$78,590-13.69%
2023-08-31SaleUroGen Pharma Ltd.
URGN
General Counsel
3,800
0.0129%
$18.01$68,438-16.42%
2023-01-31SaleUroGen Pharma Ltd.
URGN
General Counsel
1,636
0.0068%
$10.12$16,556+14.73%
2022-08-31SaleUroGen Pharma Ltd.
URGN
General Counsel
3,606
0.0153%
$7.21$25,999+29.66%
2022-01-31SaleUroGen Pharma Ltd.
URGN
General Counsel
414
0.0018%
$7.58$3,138+5.96%
2021-11-30SaleUroGen Pharma Ltd.
URGN
General Counsel
3,803
0.0169%
$12.03$45,750-31.97%
2021-05-17PurchaseUroGen Pharma Ltd.
URGN
General Counsel
5,000
0.022%
$15.71$78,550-10.34%
Total: 10
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Sells over the last 12 months, USD